{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T06:54:49Z","timestamp":1781592889717,"version":"3.54.5"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,15]]},"DOI":"10.7759\/cureus.110939","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T06:34:39Z","timestamp":1781591679000},"source":"Crossref","is-referenced-by-count":0,"title":["Time to Relapse Following Rituximab Therapy in Rheumatoid Arthritis and Its Determinants: A Single-Center Observational Study"],"prefix":"10.7759","author":[{"given":"Ikram","family":"El Moubarik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imane","family":"El binoune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Rostom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghizlane","family":"Ghoullam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bouchra","family":"Amine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma","family":"Zemrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhor","family":"Zeghari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid","family":"Bahiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: a review","volume":"320","author":"Aletaha D","year":"2018","unstructured":"Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018, 320:1360-72. 10.1001\/jama.2018.13103","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/cells9040880","article-title":"Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis","volume":"9","author":"Lin YJ","year":"2020","unstructured":"Lin YJ, Anzaghe M, Sch\u00fclke S. Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. Cells. 2020, 9:10.3390\/cells9040880","journal-title":"Cells"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1080\/25785826.2019.1660038","article-title":"Inhibitory B cell co-receptors and autoimmune diseases","volume":"42","author":"Tsubata T","year":"2019","unstructured":"Tsubata T. Inhibitory B cell co-receptors and autoimmune diseases. Immunol Med. 2019, 42:108-16. 10.1080\/25785826.2019.1660038","journal-title":"Immunol Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.765535","article-title":"Factors determining retreatment time interval of rituximab in Korean patients with rheumatoid arthritis","volume":"8","author":"Kim JW","year":"2021","unstructured":"Kim JW, Jung JY, Shin K, Suh CH, Kim HA. Factors determining retreatment time interval of rituximab in Korean patients with rheumatoid arthritis. Front Med (Lausanne). 2021, 8:765535. 10.3389\/fmed.2021.765535","journal-title":"Front Med (Lausanne)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04699-8","article-title":"A comprehensive review of rituximab therapy in rheumatoid arthritis patients","volume":"38","author":"Tavakolpour S","year":"2019","unstructured":"Tavakolpour S, Alesaeidi S, Darvishi M, et al.. A comprehensive review of rituximab therapy in rheumatoid arthritis patients. Clin Rheumatol. 2019, 38:2977-94. 10.1007\/s10067-019-04699-8","journal-title":"Clin Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S41645","article-title":"Rituximab for the treatment of rheumatoid arthritis: an update","volume":"8","author":"Mok CC","year":"2013","unstructured":"Mok CC. Rituximab for the treatment of rheumatoid arthritis: an update. Drug Des Devel Ther. 2013, 8:87-100. 10.2147\/DDDT.S41645","journal-title":"Drug Des Devel Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen SB","year":"2006","unstructured":"Cohen SB, Emery P, Greenwald MW, et al.. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006, 54:2793-806. 10.1002\/art.22025","journal-title":"Arthritis Rheum"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-015-0016-9","article-title":"Rituximab for rheumatoid arthritis","volume":"2","author":"Cohen MD","year":"2015","unstructured":"Cohen MD, Keystone E. Rituximab for rheumatoid arthritis. Rheumatol Ther. 2015, 2:99-111. 10.1007\/s40744-015-0016-9","journal-title":"Rheumatol Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12481","article-title":"Usefulness of monitoring of B cell depletion in rituximab-treated rheumatoid arthritis patients in order to predict clinical relapse: a prospective observational study","volume":"180","author":"Trouvin AP","year":"2015","unstructured":"Trouvin AP, Jacquot S, Grigioni S, et al.. Usefulness of monitoring of B cell depletion in rituximab-treated rheumatoid arthritis patients in order to predict clinical relapse: a prospective observational study. Clin Exp Immunol. 2015, 180:11-8. 10.1111\/cei.12481","journal-title":"Clin Exp Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.144998","article-title":"Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis","volume":"70","author":"Buch MH","year":"2011","unstructured":"Buch MH, Smolen JS, Betteridge N, et al.. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011, 70:909-20. 10.1136\/ard.2010.144998","journal-title":"Ann Rheum Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2019.09.021","article-title":"Factors associated with long-term persistence of rituximab in rheumatoid arthritis In clinical practice: RITAR Study","volume":"155","author":"Ca\u00f1amares Orbis I","year":"2020","unstructured":"Ca\u00f1amares Orbis I, Merino Mel\u00e9ndez L, Llorente Cubas I, et al.. Factors associated with long-term persistence of rituximab in rheumatoid arthritis In clinical practice: RITAR Study. Med Clin (Barc). 2020, 155:1-8. 10.1016\/j.medcli.2019.09.021","journal-title":"Med Clin (Barc)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/art.23902","article-title":"Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis","volume":"58","author":"Dass S","year":"2008","unstructured":"Dass S, Rawstron AC, Vital EM, Henshaw K, McGonagle D, Emery P. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum. 2008, 58:2993-9. 10.1002\/art.23902","journal-title":"Arthritis Rheum"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/ar4521","article-title":"Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patients","volume":"16","author":"Wendler J","year":"2014","unstructured":"Wendler J, Burmester GR, S\u00f6rensen H, et al.. Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patients. Arthritis Res Ther. 2014, 16:R80. 10.1186\/ar4521","journal-title":"Arthritis Res Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/art.23473","article-title":"Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment","volume":"58","author":"Roll P","year":"2008","unstructured":"Roll P, D\u00f6rner T, Tony HP. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum. 2008, 58:1566-75. 10.1002\/art.23473","journal-title":"Arthritis Rheum"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep314","article-title":"Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis","volume":"48","author":"Quartuccio L","year":"2009","unstructured":"Quartuccio L, Fabris M, Salvin S, et al.. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology (Oxford). 2009, 48:1557-9. 10.1093\/rheumatology\/kep314","journal-title":"Rheumatology (Oxford)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/BF03256352","article-title":"Response to rituximab and timeframe to relapse in rheumatoid arthritis patients: association with B-cell markers","volume":"14","author":"Pyrpasopoulou A","year":"2010","unstructured":"Pyrpasopoulou A, Douma S, Triantafyllou A, Simoulidou E, Samara M, Parapanisiou E, Aslanidis S. Response to rituximab and timeframe to relapse in rheumatoid arthritis patients: association with B-cell markers. Mol Diagn Ther. 2010, 14:43-8. 10.1007\/BF03256352","journal-title":"Mol Diagn Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-0951-z","article-title":"Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration","volume":"18","author":"Chatzidionysiou K","year":"2016","unstructured":"Chatzidionysiou K, Lie E, Nasonov E, et al.. Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. Arthritis Res Ther. 2016, 18:50. 10.1186\/s13075-016-0951-z","journal-title":"Arthritis Res Ther"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen JS","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RB, Bijlsma JW, et al.. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020, 79:685-99. 10.1136\/annrheumdis-2019-216655","journal-title":"Ann Rheum Dis"},{"key":"ref19","article-title":"Risk of tuberculosis reactivation with rituximab therapy","volume":"11","author":"Alkadi A","year":"2017","unstructured":"Alkadi A, Alduaiji N, Alrehaily A. Risk of tuberculosis reactivation with rituximab therapy. Int J Health Sci (Qassim). 2017, 11:41-4.","journal-title":"Int J Health Sci (Qassim)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/art.27359","article-title":"Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment","volume":"62","author":"Vital EM","year":"2010","unstructured":"Vital EM, Dass S, Rawstron AC, et al.. Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. Arthritis Rheum. 2010, 62:1273-9. 10.1002\/art.27359","journal-title":"Arthritis Rheum"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/502506-time-to-relapse-following-rituximab-therapy-in-rheumatoid-arthritis-and-its-determinants-a-single-center-observational-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T06:34:40Z","timestamp":1781591680000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/502506-time-to-relapse-following-rituximab-therapy-in-rheumatoid-arthritis-and-its-determinants-a-single-center-observational-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.110939","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,15]]}}}